Merck & Co. surged to all-time highs following positive Phase 3 trial results of its melanoma vaccine developed with Moderna. The company maintains a Buy rating due to strong growth in oncology, solid free cash flow, and potential for further stock gains. Despite a GAAP loss from a recent strategic acquisition, Merck's future profit outlook and capital management remain strong. Analysts see a price target range of $172 to $195, with technical support at $135, indicating room for further upside.
Bio-Techne reported Q4 revenues of $321.2 million, slightly surpassing estimates, but its adjusted EPS fell 1.9% year-over-year to $0.52, showing mixed financial results. The company's stock remains close to Merck KGaA's $73 per share acquisition off...
Merck & Co. shares have surged 72% since the last bullish call, outperforming the benchmark's 15% gain. Despite strong performance, the stock now trades at a high forward P/E ratio of 14x for 15 months ahead, with elevated earnings expectations for F...
Eli Lilly shows strong performance with 48% revenue growth driven by GLP-1 drugs Mounjaro and Zepbound, raising 2026 guidance significantly. Novo Nordisk struggles with pricing cuts and pipeline setbacks, keeping its stock range-bound despite solid s...
Moderna's stock jumped 93% following the announcement that its Phase 3 melanoma trial, conducted with Merck, met its primary endpoint by significantly improving recurrence-free survival when combined with Merck's Keytruda. This marks the first positi...
Moderna and Merck reported positive Phase 3 trial results for their personalized mRNA-based cancer vaccine combined with Keytruda, showing significant improvement in recurrence-free survival for melanoma patients. This marks the first successful Phas...
